Franciosa, GSmits, JGAMinuzzo, SMartinez-Val, AIndraccolo, SOlsen, JV2026-02-252026-02-252021-05-04Nat Commun. 2021 May 4;12(1):2507.https://hdl.handle.net/20.500.12105/27271The authors thank all lab members for feedback, especially Alexander Hogrebe, Dorte Bekker-Jensen, Nadezhda Doncheva, and Jose Romero Herrera. Work at The Novo Nordisk Foundation Center for Protein Research is funded in part by a generous donation from the Novo Nordisk Foundation (Grant number NNF14CC0001). The proteomics technology developments applied was part of a project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreements: MSmed-686547, EPIC-XS-823839, and ERC synergy grant 810057-HighResCells.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signaturesAttribution-NonCommercial-NoDerivatives 4.0 InternationalNATURE COMMUNICATIONSopen access